Details
Stereochemistry | ABSOLUTE |
Molecular Formula | C18H21N5O2 |
Molecular Weight | 339.3916 |
Optical Activity | UNSPECIFIED |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Charge | 0 |
SHOW SMILES / InChI
SMILES
CN1C(=O)C=C(N2CCC[C@@H](N)C2)N(CC3=C(C=CC=C3)C#N)C1=O
InChI
InChIKey=ZSBOMTDTBDDKMP-OAHLLOKOSA-N
InChI=1S/C18H21N5O2/c1-21-17(24)9-16(22-8-4-7-15(20)12-22)23(18(21)25)11-14-6-3-2-5-13(14)10-19/h2-3,5-6,9,15H,4,7-8,11-12,20H2,1H3/t15-/m1/s1
Molecular Formula | C18H21N5O2 |
Molecular Weight | 339.3916 |
Charge | 0 |
Count |
|
Stereochemistry | ABSOLUTE |
Additional Stereochemistry | No |
Defined Stereocenters | 1 / 1 |
E/Z Centers | 0 |
Optical Activity | UNSPECIFIED |
DescriptionCurator's Comment: description was created based on several sources, including
https://www.takeda.com/news/2013/20130924_5997.html;
http://www.ncbi.nlm.nih.gov/pubmed/22651127; http://www.ncbi.nlm.nih.gov/pubmed/17441705
Curator's Comment: description was created based on several sources, including
https://www.takeda.com/news/2013/20130924_5997.html;
http://www.ncbi.nlm.nih.gov/pubmed/22651127; http://www.ncbi.nlm.nih.gov/pubmed/17441705
Alogliptin (trade name Nesina in the US and Vipidia in Europe) is an orally administered anti-diabetic drug in the DPP-4 inhibitor class, discovered by Takeda Pharmaceutical Company's wholly owned subsidiary, Takeda San Diego, Inc. (former Syrrx) which was acquired by Takeda in 2005. Alogliptin does not decrease the risk of heart attack and stroke. Like other members of the gliptin class, it causes little or no weight gain, exhibits relatively little risk of causing hypoglycemia, and exhibits relatively modest glucose-lowering activity. Alogliptin and other gliptins are commonly used in combination with metformin in patients whose diabetes cannot adequately be controlled with metformin alone.
CNS Activity
Sources: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Public_assessment_report/human/002178/WC500152200.pdf
Curator's Comment: Alogliptin is unlikely to have untoward pharmacologic activity in the central nervous system (CNS). Although alogliptin inhibited naloxone binding at nonselective opioid receptors in vitro in the rat cerebral cortex, it did not show any binding affinity for human receptors typically associated with abuse potential (human recombinant opiate receptors).
Originator
Sources: http://www.ncbi.nlm.nih.gov/pubmed/17441705
Curator's Comment: Alogliptin was discovered by Takeda’s wholly owned subsidiary, Takeda San Diego, Inc. # Takeda San Diego, Inc.
Approval Year
Targets
Primary Target | Pharmacology | Condition | Potency |
---|---|---|---|
Target ID: P27487 Gene ID: 1803.0 Gene Symbol: DPP4 Target Organism: Homo sapiens (Human) |
Conditions
Condition | Modality | Targets | Highest Phase | Product |
---|---|---|---|---|
Secondary | NESINA Approved UseIndicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus. Limitation of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis. Launch Date1.35907194E12 |
Cmax
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
165 ng/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/ |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
154.83 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
335.36 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
75.38 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
114.08 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
246 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
55.28 ng/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
AUC
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
1511 ng × h/mL EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/ |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
1174.76 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
1625.58 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg 1 times / day multiple, oral dose: 25 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
2488.48 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
3389.21 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg 1 times / day multiple, oral dose: 50 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
601.65 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
842.17 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg 1 times / day multiple, oral dose: 12.5 mg route of administration: oral experiment type: multiple co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
1674.87999999999 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
3306.68 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
895.28 ng*h/mL Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
T1/2
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
16.9 h EXPERIMENT https://pubmed.ncbi.nlm.nih.gov/25936384/ |
25 mg 1 times / day steady-state, oral dose: 25 mg route of administration: Oral experiment type: STEADY-STATE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: HEALTHY age: ADULT sex: MALE food status: UNKNOWN |
|
21 h |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
|
20.67 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
12.5 mg single, oral dose: 12.5 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
19.45 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
25 mg single, oral dose: 25 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
|
17 h Clinical Trial https://clinicaltrials.gov/ct2/show/NCT01391663 |
50 mg single, oral dose: 50 mg route of administration: oral experiment type: single co-administered: |
ALOGLIPTIN plasma | Homo sapiens population: healthy age: Adults sex: food status: |
Funbound
Value | Dose | Co-administered | Analyte | Population |
---|---|---|---|---|
80% |
25 mg single, oral dose: 25 mg route of administration: Oral experiment type: SINGLE co-administered: |
[NO STEREO] ALOGLIPTIN plasma | Homo sapiens population: UNKNOWN age: ADULT sex: UNKNOWN food status: UNKNOWN |
Doses
Dose | Population | Adverse events |
---|---|---|
800 mg single, oral Highest studied dose |
healthy, 26.6 years (range: 18-55 years) n = 5 Health Status: healthy Age Group: 26.6 years (range: 18-55 years) Sex: M Population Size: 5 Sources: |
|
400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Other AEs: Headache, Dizziness... Other AEs: Headache (6 patients) Sources: Dizziness (4 patients) Constipation (3 patients) |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Disc. AE: Acute myocardial infarction, Angina unstable... AEs leading to discontinuation/dose reduction: Acute myocardial infarction (8 patients) Sources: Page: p. 48Angina unstable (2 patients) Myocardial infarction (12 patients) Abdominal pain (2 patients) Diarrhea (1 patient) Nausea (3 patients) Edema peripheral (4 patients) Blood creatinine increased (6 patients) Creatinine renal clearance abnormal (3 patients) Creatinine renal clearance decreased (22 patients) Lipase increased (10 patients) Hyperglycemia (3 patients) Dizziness (4 patients) Headache (2 patients) Renal impairment (13 patients) Rash (2 patients) Rash pruritic (3 patients) |
AEs
AE | Significance | Dose | Population |
---|---|---|---|
Constipation | 3 patients | 400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Dizziness | 4 patients | 400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Headache | 6 patients | 400 mg 1 times / day steady, oral Highest studied dose Dose: 400 mg, 1 times / day Route: oral Route: steady Dose: 400 mg, 1 times / day Sources: |
unhealthy, 55.6 years (range: 18 - 75 years) n = 16 Health Status: unhealthy Condition: type 2 diabetes Age Group: 55.6 years (range: 18 - 75 years) Sex: M+F Population Size: 16 Sources: |
Diarrhea | 1 patient Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Lipase increased | 10 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Myocardial infarction | 12 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Renal impairment | 13 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Abdominal pain | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Angina unstable | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Headache | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Rash | 2 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Creatinine renal clearance decreased | 22 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Creatinine renal clearance abnormal | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Hyperglycemia | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Nausea | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Rash pruritic | 3 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Dizziness | 4 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Edema peripheral | 4 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Blood creatinine increased | 6 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Acute myocardial infarction | 8 patients Disc. AE |
25 mg 1 times / day steady, oral Recommended Dose: 25 mg, 1 times / day Route: oral Route: steady Dose: 25 mg, 1 times / day Sources: Page: p. 48 |
unhealthy, adult n = 6626 Health Status: unhealthy Age Group: adult Population Size: 6626 Sources: Page: p. 48 |
Overview
CYP3A4 | CYP2C9 | CYP2D6 | hERG |
---|---|---|---|
OverviewOther
Other Inhibitor | Other Substrate | Other Inducer |
---|---|---|
Drug as perpetrator
Drug as victim
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0 |
inconclusive | no (co-administration study) Comment: cyclosporin does not have significant impact on plasma PK of SYR-322 Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=166 Page: 166151.0 |
||
no | ||||
no | ||||
no | ||||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0 |
yes | |||
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000ClinPharmR.pdf#page=164 Page: 164.0 |
yes |
Tox targets
Target | Modality | Activity | Metabolite | Clinical evidence |
---|---|---|---|---|
Sources: https://www.accessdata.fda.gov/drugsatfda_docs/nda/2013/022271Orig1s000PharmR.pdf#page=109 Page: 109.0 |
PubMed
Title | Date | PubMed |
---|---|---|
Discovery of alogliptin: a potent, selective, bioavailable, and efficacious inhibitor of dipeptidyl peptidase IV. | 2007 May 17 |
|
Alogliptin, a potent and selective dipeptidyl peptidase-IV inhibitor for the treatment of type 2 diabetes. | 2008 Apr |
|
Safety and tolerability of sitagliptin in patients with type 2 diabetes: a pooled analysis. | 2008 Oct 27 |
|
Alogliptin added to insulin therapy in patients with type 2 diabetes reduces HbA(1C) without causing weight gain or increased hypoglycaemia. | 2009 Dec |
|
Alogliptin: a new, highly selective dipeptidyl peptidase-4 inhibitor for the treatment of type 2 diabetes. | 2009 Feb |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin in patients with type 2 diabetes inadequately controlled by glyburide monotherapy. | 2009 Feb |
|
Incretin-based therapies: new treatments for type 2 diabetes in the new millennium. | 2009 Jun |
|
DPP4 inhibitors: from sitagliptin monotherapy to the new alogliptin-pioglitazone combination therapy. | 2009 Mar |
|
Diabetes treatment. | 2009 Mar |
|
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor alogliptin added to pioglitazone in patients with type 2 diabetes: a randomized, double-blind, placebo-controlled study. | 2009 Oct |
|
Coadministration of pioglitazone or glyburide and alogliptin: pharmacokinetic drug interaction assessment in healthy participants. | 2009 Oct |
|
Dipeptidyl peptidase-4 inhibitors in the management of type 2 diabetes: safety, tolerability, and efficacy. | 2010 |
|
DPP-4 (CD26) inhibitor alogliptin inhibits TLR4-mediated ERK activation and ERK-dependent MMP-1 expression by U937 histiocytes. | 2010 Dec |
|
Incretin concepts. | 2010 Feb |
|
Type 2 diabetes mellitus and the cardiometabolic syndrome: impact of incretin-based therapies. | 2010 Jul 9 |
|
Use of DPP-4 inhibitors in type 2 diabetes: focus on sitagliptin. | 2010 Mar 29 |
|
New treatments in the management of type 2 diabetes: a critical appraisal of saxagliptin. | 2010 May 10 |
|
Initial combination therapy with alogliptin and pioglitazone in drug-naïve patients with type 2 diabetes. | 2010 Nov |
|
Exenatide once weekly: clinical outcomes and patient satisfaction. | 2010 Sep 7 |
Patents
Substance Class |
Chemical
Created
by
admin
on
Edited
Sat Dec 16 17:57:30 UTC 2023
by
admin
on
Sat Dec 16 17:57:30 UTC 2023
|
Record UNII |
JHC049LO86
|
Record Status |
Validated (UNII)
|
Record Version |
|
-
Download
Name | Type | Language | ||
---|---|---|---|---|
|
Official Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English | ||
|
Common Name | English |
Classification Tree | Code System | Code | ||
---|---|---|---|---|
|
WHO-ATC |
A10BH04
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
||
|
NCI_THESAURUS |
C98086
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
||
|
WHO-ATC |
A10BD09
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
||
|
WHO-VATC |
QA10BD13
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
||
|
WHO-ATC |
A10BD13
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
||
|
WHO-VATC |
QA10BD09
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
||
|
WHO-VATC |
QA10BH04
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
||
|
NDF-RT |
N0000175913
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
Code System | Code | Type | Description | ||
---|---|---|---|---|---|
|
Alogliptin
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
8814
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
1368001
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | RxNorm | ||
|
8203
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
72323
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
JHC049LO86
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
ALOGLIPTIN
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
DTXSID90234130
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
DB06203
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
C76906
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
C520853
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
850649-61-5
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
CHEMBL376359
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
11450633
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
SUB32564
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
6319
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
m1572
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | Merck Index | ||
|
JHC049LO86
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
100000124299
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY | |||
|
4340
Created by
admin on Sat Dec 16 17:57:31 UTC 2023 , Edited by admin on Sat Dec 16 17:57:31 UTC 2023
|
PRIMARY |
Related Record | Type | Details | ||
---|---|---|---|---|
|
SALT/SOLVATE -> PARENT | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
METABOLIC ENZYME -> SUBSTRATE | |||
|
EXCRETED UNCHANGED |
URINE
|
||
|
TARGET -> INHIBITOR |
IC50
|
||
|
BINDER->LIGAND |
BINDING
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
METABOLITE ACTIVE -> PARENT |
MINOR
|
||
|
METABOLITE INACTIVE -> PARENT |
MINOR
|
Related Record | Type | Details | ||
---|---|---|---|---|
|
ACTIVE MOIETY |
Name | Property Type | Amount | Referenced Substance | Defining | Parameters | References |
---|---|---|---|---|---|---|
Volume of Distribution | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
Tmax | PHARMACOKINETIC |
|
SINGLE DOSE |
|
||
Biological Half-life | PHARMACOKINETIC |
|
|
|||